ID SYI_MALP2 Reviewed; 900 AA. AC Q8EUN9; DT 20-DEC-2005, integrated into UniProtKB/Swiss-Prot. DT 01-MAR-2003, sequence version 1. DT 27-MAR-2024, entry version 123. DE RecName: Full=Isoleucine--tRNA ligase {ECO:0000255|HAMAP-Rule:MF_02002}; DE EC=6.1.1.5 {ECO:0000255|HAMAP-Rule:MF_02002}; DE AltName: Full=Isoleucyl-tRNA synthetase {ECO:0000255|HAMAP-Rule:MF_02002}; DE Short=IleRS {ECO:0000255|HAMAP-Rule:MF_02002}; GN Name=ileS {ECO:0000255|HAMAP-Rule:MF_02002}; GN OrderedLocusNames=MYPE8820; OS Malacoplasma penetrans (strain HF-2) (Mycoplasma penetrans). OC Bacteria; Mycoplasmatota; Mycoplasmoidales; Mycoplasmoidaceae; OC Malacoplasma. OX NCBI_TaxID=272633; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RC STRAIN=HF-2; RX PubMed=12466555; DOI=10.1093/nar/gkf667; RA Sasaki Y., Ishikawa J., Yamashita A., Oshima K., Kenri T., Furuya K., RA Yoshino C., Horino A., Shiba T., Sasaki T., Hattori M.; RT "The complete genomic sequence of Mycoplasma penetrans, an intracellular RT bacterial pathogen in humans."; RL Nucleic Acids Res. 30:5293-5300(2002). CC -!- FUNCTION: Catalyzes the attachment of isoleucine to tRNA(Ile). As IleRS CC can inadvertently accommodate and process structurally similar amino CC acids such as valine, to avoid such errors it has two additional CC distinct tRNA(Ile)-dependent editing activities. One activity is CC designated as 'pretransfer' editing and involves the hydrolysis of CC activated Val-AMP. The other activity is designated 'posttransfer' CC editing and involves deacylation of mischarged Val-tRNA(Ile). CC {ECO:0000255|HAMAP-Rule:MF_02002}. CC -!- CATALYTIC ACTIVITY: CC Reaction=ATP + L-isoleucine + tRNA(Ile) = AMP + diphosphate + L- CC isoleucyl-tRNA(Ile); Xref=Rhea:RHEA:11060, Rhea:RHEA-COMP:9666, CC Rhea:RHEA-COMP:9695, ChEBI:CHEBI:30616, ChEBI:CHEBI:33019, CC ChEBI:CHEBI:58045, ChEBI:CHEBI:78442, ChEBI:CHEBI:78528, CC ChEBI:CHEBI:456215; EC=6.1.1.5; Evidence={ECO:0000255|HAMAP- CC Rule:MF_02002}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000255|HAMAP- CC Rule:MF_02002}; CC Note=Binds 1 zinc ion per subunit. {ECO:0000255|HAMAP-Rule:MF_02002}; CC -!- SUBUNIT: Monomer. {ECO:0000255|HAMAP-Rule:MF_02002}. CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000255|HAMAP-Rule:MF_02002}. CC -!- DOMAIN: IleRS has two distinct active sites: one for aminoacylation and CC one for editing. The misactivated valine is translocated from the CC active site to the editing site, which sterically excludes the CC correctly activated isoleucine. The single editing site contains two CC valyl binding pockets, one specific for each substrate (Val-AMP or Val- CC tRNA(Ile)). {ECO:0000255|HAMAP-Rule:MF_02002}. CC -!- SIMILARITY: Belongs to the class-I aminoacyl-tRNA synthetase family. CC IleS type 1 subfamily. {ECO:0000255|HAMAP-Rule:MF_02002}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; BA000026; BAC44673.1; -; Genomic_DNA. DR RefSeq; WP_011077702.1; NC_004432.1. DR AlphaFoldDB; Q8EUN9; -. DR SMR; Q8EUN9; -. DR STRING; 272633.gene:10732004; -. DR KEGG; mpe:MYPE8820; -. DR eggNOG; COG0060; Bacteria. DR HOGENOM; CLU_001493_7_0_14; -. DR InParanoid; Q8EUN9; -. DR Proteomes; UP000002522; Chromosome. DR GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0002161; F:aminoacyl-tRNA editing activity; IEA:InterPro. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-UniRule. DR GO; GO:0004822; F:isoleucine-tRNA ligase activity; IEA:UniProtKB-UniRule. DR GO; GO:0000049; F:tRNA binding; IEA:InterPro. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-UniRule. DR GO; GO:0006428; P:isoleucyl-tRNA aminoacylation; IEA:UniProtKB-UniRule. DR CDD; cd07960; Anticodon_Ia_Ile_BEm; 1. DR CDD; cd00818; IleRS_core; 1. DR Gene3D; 1.10.730.20; -; 1. DR Gene3D; 3.40.50.620; HUPs; 2. DR Gene3D; 3.90.740.10; Valyl/Leucyl/Isoleucyl-tRNA synthetase, editing domain; 1. DR HAMAP; MF_02002; Ile_tRNA_synth_type1; 1. DR InterPro; IPR002300; aa-tRNA-synth_Ia. DR InterPro; IPR033708; Anticodon_Ile_BEm. DR InterPro; IPR002301; Ile-tRNA-ligase. DR InterPro; IPR023585; Ile-tRNA-ligase_type1. DR InterPro; IPR013155; M/V/L/I-tRNA-synth_anticd-bd. DR InterPro; IPR014729; Rossmann-like_a/b/a_fold. DR InterPro; IPR009080; tRNAsynth_Ia_anticodon-bd. DR InterPro; IPR009008; Val/Leu/Ile-tRNA-synth_edit. DR NCBIfam; TIGR00392; ileS; 1. DR PANTHER; PTHR42765:SF1; ISOLEUCINE--TRNA LIGASE, MITOCHONDRIAL; 1. DR PANTHER; PTHR42765; SOLEUCYL-TRNA SYNTHETASE; 1. DR Pfam; PF08264; Anticodon_1; 1. DR Pfam; PF00133; tRNA-synt_1; 1. DR PRINTS; PR00984; TRNASYNTHILE. DR SUPFAM; SSF47323; Anticodon-binding domain of a subclass of class I aminoacyl-tRNA synthetases; 1. DR SUPFAM; SSF52374; Nucleotidylyl transferase; 1. DR SUPFAM; SSF50677; ValRS/IleRS/LeuRS editing domain; 1. PE 3: Inferred from homology; KW Aminoacyl-tRNA synthetase; ATP-binding; Cytoplasm; Ligase; Metal-binding; KW Nucleotide-binding; Protein biosynthesis; Reference proteome; Zinc. FT CHAIN 1..900 FT /note="Isoleucine--tRNA ligase" FT /id="PRO_0000098423" FT MOTIF 58..68 FT /note="'HIGH' region" FT MOTIF 591..595 FT /note="'KMSKS' region" FT BINDING 550 FT /ligand="L-isoleucyl-5'-AMP" FT /ligand_id="ChEBI:CHEBI:178002" FT /evidence="ECO:0000255|HAMAP-Rule:MF_02002" FT BINDING 594 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|HAMAP-Rule:MF_02002" FT BINDING 871 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|HAMAP-Rule:MF_02002" FT BINDING 874 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|HAMAP-Rule:MF_02002" FT BINDING 888 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|HAMAP-Rule:MF_02002" FT BINDING 891 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|HAMAP-Rule:MF_02002" SQ SEQUENCE 900 AA; 104162 MW; E7710FE7B619458C CRC64; MSDYKKTLSM PNTNFEMKAN LSVKETKIQE NWVLEKIEKK ILAKNKSNTP FIIADGPPYA NGDLHTGHAL NKILKDIILR FKASVGFYTK YIPGWDTHGL PIEQEMAKRG LNKNANQTIT EKRKNCKNFA IENVYKQRDQ FRRLGILSEM DEIYVTCDLD YVIRQIKIFN KMLSKGLIYQ DLKPVYWSWS SQTALADAEI IYQDVESDSI YVSLEILDKN EFVSKGDKVI IWTTTPWTLP SNLAIAANPK VTYCRVQVEN SVYVISKNLV EKLAETLEWT NYEILSEFSG KKLENLPYKS PISDKKCKII VDGYVSDSDG TGLVHNAPGF GHEDYLACKK YNIKPYCPID NLGKFTGEVN DKELAGLFYK DANPIIIERL AKKKLLLKAS KFTHSAAHDW RTKKPVIYRA TKQWFVNIDK ISKEIVAALN KVKSIDNTII KKIKEMVLNR QEWCISRQRI WGVPICIIYD KDYNPILDPK LLNNIVDILN DEGINAWYNE DAKYFLTDSY NTSKKYIKET DIMDVWFDSG TSYSVLQADK LGYPADLYFE GKDQFRGWFN SSLITSVAAF KKSPYKELLT HGFVLDENGN KMSKSLGNII DPLQVCKEYG ADVLRLWVAS VDFSKDVSIS KDIIAQNAEL YRRIRNTLFR FILGNLNGFN LKKLRGAKYS EADLYVLSCL SNDIKTIKAC YDKYDFKQIV KIVSKNVADL SSWYFDYIKD PLYCEKEDNE QRIAIQATLY QLLDSYLRIL APIIPHTCEE AYEFFDKKDK QKSVHLEGFT NFKIDSKYKV DFKKWEEFFD LKDKVYSEIE KTRNEKVINS KGQAHITIHS KSLPFDEQTL ERYLGVAKVE FKVKEKDGTT IKVKNSKYAR CERCWNYYPT NLIANELCER CKKVIGNKKI //